Dolat Capital is bullish on Ipca Laboratories and has recommended accumulate rating on the stock with a target of Rs 487 in its September 14, 2012 research report.
"IPCA has transformed itself from a leading API manufacturer to a fully integrated formulation company. We anticipate domestic formulations to sustain growth trajectory from hereon (16% CAGR over FY12-14E) aided by growth in CVS & pain management. We expect export formulations to register 21% growth over FY12-14E mainly driven by increasing ramp up in its US generics biz and higher contribution from institutional based sales
Firstcall Research is bullish on IndusInd Bank and has recommended buy rating on the stock with a target of Rs 345 in its September 14, 2012 research report.
"IndusInd Bank derives its name and inspiration from the Indus Valley civilization. IndusInd Bank, which commenced its operations in 1994, caters to the needs of both consumer and corporate customers. It has a robust technology platform supporting multi-channel delivery capabilities. IndusInd Bank has 421 branches, and 735 ATMs spread across 288 geographic locations of the country as on June 30, 2012. The Bank also has 2 Representative offices, one each in London and Dubai.
Emkay Global is bullish on the IRB Infrastructure Developers Ltd and has recommended buy rating with target price of Rs 193.
The management of IRB Infrastructure developers Ltd id confident of maintaining the high margin of over 20% in the engineering, procurement and construction segment, strong operating cash flow to finance equity commitment, moderate growth in toll collection and comfortable leverage.
Emkay Global bullish on Bharat Petroleum Corp. Ltd (BPCL) and has recommended accumulate rating on the stock with a target of Rs 623.
Bharat Petroleum Corp. Ltd (BPCL) reported results which were below our estimates at earnings before interest, tax, depreciation and amortization and profit after tax levels, primarly due to cash compensation received from the government during the quarter. Revenue for the quarter was Rs 42,300 crore.
DISCLAIMER: GoodReturns provides you with information covering shares, futures and options based on broker's reports as stated on various media. Investors are, however, warned that they should NOT take any buy or sell decision based on these views expressed in the article. Investors should consult their own financial and share advisors before taking purchase or sale decisions. GoodReturns does not take any responsibility for any losses incurred by investors who take their cues from the above article.